Research search

Reset all

287 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Journal: ClinicalTrials.gov 287 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 3, 2026 00:16 UTC

Checking for newly published papers…

287 matching results

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly understood. The proposed work will address these questions i...

ClinicalTrials.gov 2025-10-20 University of California, Berkeley

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingMechanism of ActionAging Other Perception DisordersPsilocybin

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation

Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-...

ClinicalTrials.gov 2025-10-14 University of Wisconsin, Madison

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionChronic PainClinical TrialObservational StudySafetyAdverse Events Clinical Trial Opioid Use DisorderPsilocybin with facilitated counseling

A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer

This phase I trial tests the safety and side effects of a second episode of psilocybin-assisted group therapy and how well it works in treating anxiety and distress in patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and had a partial response to their first retreat. Up to 50% of patient...

ClinicalTrials.gov 2025-10-13 University of Washington

ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyReceptor PharmacologyWellbeingClinical TrialSafetyAdverse Events Clinical Trial Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid Neoplasm

Psilocybin and Affective Function in Chronic Lower Back Pain Depression

This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depre...

ClinicalTrials.gov 2025-10-13 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionChronic PainMechanism of ActionObservational StudySafety Observational Study Chronic Low-back PainDepression

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose i...

ClinicalTrials.gov 2025-10-09 Oregon Health and Science University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Chronic PainSafetyAdverse Events Other Chronic Pelvic PainPsilocybin (Usona Institute)

A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine

The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive...

ClinicalTrials.gov 2025-10-06 Kevin Murnane

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionEmotional ProcessingReview ArticleSafety Review Article Methamphetamine Use DisorderPsilocybin 25 mg

Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects. The benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed. Moreover, the role of 5-HT2A receptors, involved in the psychedelic experience, on th...

ClinicalTrials.gov 2025-10-06 Centre Hospitalier St Anne

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionReceptor PharmacologyClinical TrialRandomized Controlled TrialTreatment-Resistant DepressionSafety Randomized Controlled Trial Depression - Major Depressive DisorderTreatment-resistant Depression (TRD)

Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment

This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive disorders. Data will be analyzed from patients treated at the University Hospitals of Geneva between June 2020 and April 2025 who obt...

ClinicalTrials.gov 2025-10-01 University Hospital, Geneva

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyPTSDAddictionObservational StudyTreatment-Resistant DepressionSafety Observational Study Major Depressive Disorder (MDD)Anxiety Disorders

Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)

The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet The proposed randomized, double-blind, active control study will compare a single exper...

ClinicalTrials.gov 2025-09-30 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDVeteransSafety Clinical Trial Posttraumatic Stress DisorderPsilocybin

An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy

The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is "Does mindfulness training enhance the effects of psychedelic therapy (psilocybin) on mental health?" Interested individuals will complete an initial eligibility session and eligible participants will then b...

ClinicalTrials.gov 2025-09-25 University of Southern California

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingMechanism of ActionBiomarkersSpiritualityClinical TrialObservational StudySafetyAdverse EventsInflammation Clinical Trial Mental HealthPsilocybin plus mindfulness training

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

The purpose for this study is to observe the real world experience of participants who are receiving psilocybin in the context of (alcoholism) Alcohol Use Disorder without intervening in the model of care. The study team will engage directly with the participants to examine the outcomes in participants who have been deemed eligible and appropriate to receive...

ClinicalTrials.gov 2025-09-23 Healing Advocacy Fund

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyPTSDAddictionWellbeingClinical TrialObservational StudySafety Clinical Trial Alcohol Use Disorderpsilocybin

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

The goal of this clinical trial is to understand how personally meaningful, autobiographically salient music compares to standardized playlists when combined with psilocybin in healthy adults ages 21 to 75. The main questions it aims to answer are: Does autobiographically salient music lead to stronger emotional responses to music, greater acute subjective e...

ClinicalTrials.gov 2025-09-17 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingConsciousnessWellbeingEmotional ProcessingClinical Trial Clinical Trial PsilocybinMusic Intervention

The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.

Rationale: Recent evidence shows that Lysergic Acid Diethylamide (LSD), even when administered in low, non-hallucinogenic doses, can produce analgesic effects and improve pain tolerance in a sample of healthy volunteers. Such results complement what was already observed with other serotonergic psychedelics such as psilocybin: survey studies and case series i...

ClinicalTrials.gov 2025-09-14 Maastricht University

ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyChronic PainHeadache / MigraineReview ArticleCase ReportObservational StudyHealthy VolunteersSafety Clinical Trial FibromyalgiaPsilocybin

Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.

About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial challenges, and a higher risk of suicide. Psilocybin-a compound found in certain mushrooms-has shown early promise as a new treatment for thi...

ClinicalTrials.gov 2025-09-09 King's College London

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionReceptor PharmacologyBiomarkersClinical TrialAnimal StudyIn Vitro StudyTreatment-Resistant DepressionSafetyInflammationImmune Function Clinical Trial Depression - Major Depressive DisorderACTIVE_NOT_RECRUITING

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes...

ClinicalTrials.gov 2025-09-07 Rachel Yehuda

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyBiomarkersWellbeingResilienceHealthcare WorkersSafety Other Psychological StressDepression

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial

This randomized controlled clinical trial evaluates the effectiveness of psilocybin and psilocybin-assisted cognitive behavioral therapy (CBT) in the management of Major Depressive Disorder (MDD). The study aims to compare the effects of psilocybin-only therapy, CBT, and psilocybin-assisted CBT on depression symptoms, neurochemical markers, inflammatory mark...

ClinicalTrials.gov 2025-09-01 Khyber Medical University Peshawar

ClinicalTrials.gov CLINICAL TRIAL psilocybinpsilocin DepressionNeuroplasticityBrain ImagingBiomarkersClinical TrialRandomized Controlled TrialInflammationImmune Function Randomized Controlled Trial Major Depressive DisorderPsilocybin

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and post...

ClinicalTrials.gov 2025-08-27 Nathan Brashares Sackett

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDAddictionClinical TrialVeteransSafety Clinical Trial Alcohol Use Disorder (AUD)PTSD

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

Psychogenic non-epileptic seizures (PNES) are functional paroxysmal motor disorders that may be clinically suggestive of epilepsy but are not associated with the electroencephysiological and electroencephalographic changes of epilepsy. Thus, hyper-connectivity of the regions of the default mode network (DMN) linked to executive control could be involved in t...

ClinicalTrials.gov 2025-08-20 Centre Hospitalier Universitaire de Nīmes

ClinicalTrials.gov CLINICAL TRIAL psilocybin Default Mode NetworkEmotional Processing Other Psychogenic Nonepileptic SeizuresPsilocybin

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study

The study hypothesis is that the antidepressant effect of psilocybin is mediated by a normalization of the functioning of the positive valence system. Depressive states, especially moderate to severe depressions that associate a certain level of anhedonia, produce an overvaluation of the cost of efforts and an infra-evaluation of the possible rewards derived...

ClinicalTrials.gov 2025-08-19 Centre Hospitalier Universitaire de Nīmes

ClinicalTrials.gov CLINICAL TRIAL psilocybinpsilocin DepressionBrain ImagingMechanism of ActionReceptor PharmacologyAgingTreatment-Resistant DepressionSafety Other Depressive DisorderDepressive Disorder

Effects of Psilocybin in Post-Treatment Lyme Disease

This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD). This pilot study will evaluate the therapeutic potential of psilocybin in people with well-documented current Post-Treatment Lyme Disease (PTLD). Study measures will assess the impact of psilocybin-assisted t...

ClinicalTrials.gov 2025-08-19 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin General Other Post-Treatment Lyme DiseaseChronic Lyme Disease

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications